LCTX
Price
$0.68
Change
+$0.02 (+3.03%)
Updated
Jun 6 closing price
Capitalization
154.19M
61 days until earnings call
MDGL
Price
$278.23
Change
+$4.13 (+1.51%)
Updated
Jun 6 closing price
Capitalization
6.18B
60 days until earnings call
Interact to see
Advertisement

LCTX vs MDGL

Header iconLCTX vs MDGL Comparison
Open Charts LCTX vs MDGLBanner chart's image
Lineage Cell Therapeutics
Price$0.68
Change+$0.02 (+3.03%)
Volume$874.94K
Capitalization154.19M
Madrigal Pharmaceuticals
Price$278.23
Change+$4.13 (+1.51%)
Volume$279.61K
Capitalization6.18B
LCTX vs MDGL Comparison Chart
Loading...
LCTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MDGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
LCTX vs. MDGL commentary
Jun 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LCTX is a StrongBuy and MDGL is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 07, 2025
Stock price -- (LCTX: $0.68 vs. MDGL: $278.23)
Brand notoriety: LCTX and MDGL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: LCTX: 84% vs. MDGL: 77%
Market capitalization -- LCTX: $154.19M vs. MDGL: $6.18B
LCTX [@Biotechnology] is valued at $154.19M. MDGL’s [@Biotechnology] market capitalization is $6.18B. The market cap for tickers in the [@Biotechnology] industry ranges from $324.3B to $0. The average market capitalization across the [@Biotechnology] industry is $2.35B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

LCTX’s FA Score shows that 0 FA rating(s) are green whileMDGL’s FA Score has 0 green FA rating(s).

  • LCTX’s FA Score: 0 green, 5 red.
  • MDGL’s FA Score: 0 green, 5 red.
According to our system of comparison, LCTX is a better buy in the long-term than MDGL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

LCTX’s TA Score shows that 5 TA indicator(s) are bullish while MDGL’s TA Score has 6 bullish TA indicator(s).

  • LCTX’s TA Score: 5 bullish, 4 bearish.
  • MDGL’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, MDGL is a better buy in the short-term than LCTX.

Price Growth

LCTX (@Biotechnology) experienced а +1.58% price change this week, while MDGL (@Biotechnology) price change was +1.08% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.04%. For the same industry, the average monthly price growth was +14.90%, and the average quarterly price growth was +1.90%.

Reported Earning Dates

LCTX is expected to report earnings on Aug 07, 2025.

MDGL is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (+9.04% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MDGL($6.18B) has a higher market cap than LCTX($154M). LCTX YTD gains are higher at: 34.368 vs. MDGL (-9.832). LCTX has higher annual earnings (EBITDA): -20.87M vs. MDGL (-376.15M). MDGL has more cash in the bank: 843M vs. LCTX (47.8M). LCTX has less debt than MDGL: LCTX (2.51M) vs MDGL (120M). MDGL has higher revenues than LCTX: MDGL (317M) vs LCTX (9.5M).
LCTXMDGLLCTX / MDGL
Capitalization154M6.18B2%
EBITDA-20.87M-376.15M6%
Gain YTD34.368-9.832-350%
P/E RatioN/AN/A-
Revenue9.5M317M3%
Total Cash47.8M843M6%
Total Debt2.51M120M2%
FUNDAMENTALS RATINGS
LCTX vs MDGL: Fundamental Ratings
LCTX
MDGL
OUTLOOK RATING
1..100
1355
VALUATION
overvalued / fair valued / undervalued
1..100
39
Fair valued
63
Fair valued
PROFIT vs RISK RATING
1..100
10045
SMR RATING
1..100
9294
PRICE GROWTH RATING
1..100
3962
P/E GROWTH RATING
1..100
64100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

LCTX's Valuation (39) in the null industry is in the same range as MDGL (63) in the Pharmaceuticals Other industry. This means that LCTX’s stock grew similarly to MDGL’s over the last 12 months.

MDGL's Profit vs Risk Rating (45) in the Pharmaceuticals Other industry is somewhat better than the same rating for LCTX (100) in the null industry. This means that MDGL’s stock grew somewhat faster than LCTX’s over the last 12 months.

LCTX's SMR Rating (92) in the null industry is in the same range as MDGL (94) in the Pharmaceuticals Other industry. This means that LCTX’s stock grew similarly to MDGL’s over the last 12 months.

LCTX's Price Growth Rating (39) in the null industry is in the same range as MDGL (62) in the Pharmaceuticals Other industry. This means that LCTX’s stock grew similarly to MDGL’s over the last 12 months.

LCTX's P/E Growth Rating (64) in the null industry is somewhat better than the same rating for MDGL (100) in the Pharmaceuticals Other industry. This means that LCTX’s stock grew somewhat faster than MDGL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
LCTXMDGL
RSI
ODDS (%)
Bearish Trend 1 day ago
71%
Bullish Trend 1 day ago
76%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
80%
Bullish Trend 1 day ago
76%
Momentum
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
79%
MACD
ODDS (%)
N/A
Bullish Trend 1 day ago
81%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
75%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
82%
Bearish Trend 1 day ago
81%
Advances
ODDS (%)
Bullish Trend 4 days ago
76%
Bullish Trend about 1 month ago
77%
Declines
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
81%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
78%
Aroon
ODDS (%)
Bullish Trend 1 day ago
80%
Bearish Trend 1 day ago
77%
View a ticker or compare two or three
Interact to see
Advertisement
LCTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MDGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
NWLG34.630.45
+1.30%
Nuveen Winslow Large-Cap Growth ESG ETF
VUSE61.630.39
+0.64%
Vident U.S. Equity Strategy ETF
SEPW29.650.17
+0.58%
AllianzIM U.S. Large Cp Buffer20 Sep ETF
COM28.470.05
+0.16%
Direxion Auspice Broad Cmdty Strat ETF
IBDR24.14-0.01
-0.04%
iShares iBonds Dec 2026 Term Corp ETF

LCTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, LCTX has been loosely correlated with MDGL. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if LCTX jumps, then MDGL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LCTX
1D Price
Change %
LCTX100%
+2.77%
MDGL - LCTX
43%
Loosely correlated
+1.51%
ABCL - LCTX
36%
Loosely correlated
+2.95%
ATOS - LCTX
36%
Loosely correlated
+4.69%
ATAI - LCTX
36%
Loosely correlated
-2.82%
BEAM - LCTX
35%
Loosely correlated
+9.26%
More